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We have examined human immunodeficiency virus type 1 (HIV-1) infection in chimpanzees by analyzing
HIV-1 DNA and RNA in lymph nodes and peripheral mononuclear cells (PBMCs). Like certain asymptomatic
HIV-infected persons, these chimpanzees had no detectable viral replication in their PBMCs. However, viral
replication and a high viral load were observed in the lymphatic tissue. Despite the absence of viral replication
in PBMCs, 1/1,000 to 1/10,000 of the PBMCs contained HIV-1 proviral DNA, and HIV transcription could be
rapidly induced in these cells in vitro. These results provide direct evidence of cellular latency of HIV in vivo
and suggest that HIV infection in chimpanzees may be a useful model for clinical latency of HIV infection in
humans.
Chimpanzees can be infected with relatively low doses of
human immunodeficiency virus type 1 (HIV-1), resulting in an
infection that is in many ways similar to that of humans (1, 13,
19). As in humans (29), HIV-1 infection in chimpanzees results
in a transient viremia followed by an extended period with low
or undetectable levels of cell-free virus in plasma and few
infected cells in the peripheral blood (14-16). Chimpanzees
also develop HIV-specific neutralizing antibodies (15, 25, 26)
and cytotoxic T cells (4, 7, 39). Despite these immunological
responses, persistent viral replication occurs, and infectious
virus can typically be isolated from chimpanzee peripheral
blood mononuclear cells (PBMCs) at any time of the infection
(2, 14, 15, 26).
Although episodes of lymphadenopathy (1, 22) and cases of
decreased numbers of CD4-positive lymphocytes accompanied
by thrombocytopenia (18) have been reported, for reasons that
are currently not well understood, none of the more than 100
chimpanzees infected with HIV-1 have so far have developed
AIDS. Nevertheless, it is apparent that many features in the
pathobiology of HIV infection are shared between humans and
chimpanzees. The persistent infection in chimpanzees despite
a specific immune response and the absence of overt disease
suggests a virus-host interaction that might be similar to that in
HIV-positive asymptomatic humans.
A lower level of viral gene expression (HIV-1 mRNA) and
fewer HIV-infected cells (proviral DNA) are typically ob-
served in the peripheral blood of HIV-infected persons during
the asymptomatic phase of the disease than in later stages of
the infection (3, 9, 23, 28, 34). We have recently extended these
observations by analyzing serial PBMC samples collected
during a long-term prospective study. We found that the
expression of HIV mRNA differs dramatically among HIV-
infected individuals with very similar clinical indices, and this
variation strongly correlates with the future course of their
disease (32). Significantly, we found no evidence of viral
replication in the blood of long-term asymptomatic HIV
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carriers who would continue to have normal numbers of CD4+
cells for more than 5 years.
Although HIV replication in PBMCs is variable over the
course of the disease, it has been suggested that lymphoid
germinal centers are an important reservoir of HIV and
support active viral replication in all stages of HIV infection (8,
12, 27, 28). Notably, high viral load has been demonstrated in
the lymphatic tissues of asymptomatic individuals with little or
no detectable viral replication in their peripheral blood (28).
In all stages of the disease, the number of cells harboring
HIV provirus appears to be larger than the number of cells
expressing HIV-1 mRNA (8, 21, 35). It is somewhat contro-
versial whether this ratio significantly changes during the
progression of the disease (3, 8, 23); if it does, a possible
explanation could be an increase in the number of new
productively infected cells rather than transcriptional activa-
tion of quiescent proviruses in latently infected cells. There-
fore, it is not known whether latently infected cells which can
be productively activated exist in vivo.
In this study, we have used HIV-infected chimpanzees as a
model system with which to study HIV growth in vivo. We have
compared the viral nucleic acid load in the lymph nodes (LN)
and peripheral blood of these animals by quantitative poly-
merase chain reaction (PCR) assays specific for HIV-1 DNA
and RNA. These studies have revealed a dramatically higher
amount of HIV-1 RNA in chimpanzee LN than in their
PBMCs. However, a short stimulation of PBMCs in vitro was
sufficient to induce readily detectable expression of HIV-1
mRNA, providing direct evidence that cells with a transcrip-
tionally competent but yet quiescent HIV exist in vivo.
MATERIALS AND METHODS
Chimpanzees. Chimpanzee C-487 (male) was infected intra-
venously with a chimpanzee-passaged lymphadenopathy-asso-
ciated virus 1 (LAV-1) strain, LAV-lb (37), 4.5 years before
the analyzed samples were obtained and has been described in
detail previously (14). C-435 (male) was infected 3 years before
sampling by transfusion of 7 x 105 PBMCs from another
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HIV-11,i-infected chimpanzee (C-087 in reference 20). A
more detailed description of the infection and follow-up of
C-435 is reported in reference 17. C-120 (female) was infected
10 months before sample collection via the endocervical-
vaginal route, using an inoculum of 107 PBMCs from C-435.
C-120 became virus positive in PBMCs at week 4 postinfection
and seroconverted quickly thereafter. All chimpanzees were
maintained in biosafety level 2 and 3 facilities at the Labora-
tory for Experimental Medicine and Surgery in Primates, and
the experimental procedures were performed according to
accepted practices for the care and use of primates in biomed-
ical research.
Sample collection and preparation. Peripheral blood and
inguinal LN biopsies were obtained simultaneously under
ketamine anesthesia. The LN biopsies were frozen on dry ice
and stored at - 70°C until analyzed. PBMCs were purified
immediately after the blood was drawn by using Ficoll-
Hypaque (Pharmacia) centrifugation, washed twice with RPMI
1640, and either stored as a frozen pellet until analyzed or
resuspended in RPMI 1640 with 10% fetal calf serum plus
antibiotics when used for in vitro activation studies. These cells
were kept at room temperature until split into aliquots and put
into culture I h later. The unstimulated control sample was
harvested at this point. Phorbol 12-myristate 13-acetate
(PMA) and phytohemagglutinin (PHA) were purchased from
Sigma and used as specified in the text.
Nucleic acid extractions and PCR assays. Total RNA was
extracted by the acid phenol-guanidium isothiocyanate method
(5). The RNA preparations were then treated for 1 h with 100
U of RNase-free DNase (Boehringer Mannheim) in the pres-
ence of 50 U of placental RNase inhibitor (Boehringer
Mannheim), extracted with phenol-chloroform, and precipi-
tated with ethanol. High-molecular-weight DNA was extracted
by standard methods and incubated for 1 h with 100 U of
boiled RNase A (Boehringer Mannheim) before addition of
proteinase K to the lysates. The reverse transcription-PCR
(RT-PCR) analysis of the RNA samples was performed as
follows. One microgram of DNase-treated RNA in 20 p.l of
water was heated for 5 min at 80°C, transferred onto ice, and
combined with a mixture containing 6 pL. of 5 x reaction buffer
(250 mM Tris [pH 8.3], 375 mM KCl, 15 mM MgCI2), 1.5 p.1 of
deoxynucleoside triphosphates (dNTPs; 10 mM each), 0.6 p.l of
RNasin, I IlI of random hexamers (1 mM; Pharmacia), and 2
,ul of Moloney murine leukemia virus reverse transcriptase
(Gibco-BRL) or 2 p. of water in the control lacking enzyme.
After a 1-h incubation at 42°C, 2 p.1 samples of these reverse
transcription reactions were added to each 50-plI PCR mixture
containing 10 mM Tris (pH 8.5), 50 mM KCl, 1.5 mM MgCl2,
0.02% gelatin, 50 p.M each unlabeled dNTP, 100 ng of each
23-mer oligonucleotide primer, 0.25 p. of [oX_32P]dCTP (3,000
Ci/mmol; NEN), and 0.25 p.1 of Taq polymerase (5 U/pl;
Boehringer). These reactions were cycled in tightly fitting
tubes under mineral oil in a Perkin-Elmer Cetus DNA Ther-
mal Cycler 480 as follows: one cycle of 94°C for 40 s, 65°C for
1 min, and 72°C for 30 s, followed by 32 cycles of 94°C for 20
s, 65°C for 30 s, and 72°C for 20 s. r-Actin PCRs were cycled
only 22 times after the first cycle, using the conditions specified
above, and 10% dimethyl sulfoxide was added to inhibit
primer-dimer formation. The sequences (sense and then anti-
sense) of the oligonucleotides used were as follows: unspliced
(US) HIV-1, 5'-TCT CTA GCA GTG GCG CCC GAA CA-3'
and 5'-TCT CCT TCT AGC CTC CGC TAG TC-3'; multiply
spliced (MS) HIV-1, 5'-CTT AGG CAT CTC CTA TGG
CAG GAA-3' and 5'-TTC CTT CGG GCC TGT CGG GTC
CC-3'; and 13-actin, 5'-CGA GCA CAG AGC CTC GCC YTT
GC-3' and 5'-CAT AGG AAT CCT TCT GAC CCA TG-3'.
To confirm the lack of contaminating proviral HIV-1 DNA in
the PBMC cDNA preparations, a duplicate cDNA synthesis of
each sample was also performed without adding reverse tran-
scriptase and analyzed in a US HIV-1 PCR assay. In addition,
in each set of RNA extractions, a negative control with 20 p.g
of yeast tRNA and no cells added to the lysis buffer was
processed together with the PBMC preparations and analyzed
in MS and US HIV-1 RT-PCR to exclude any contamination
of the samples during sample processing or RT-PCR analysis.
Quantitations of the HIV-1-specific RNA were based on
comparisons of the intensities of the autoradiographic PCR
signals from the chimpanzee samples with those derived from
parallel analyses of in vitro-transcribed HIV-1 RNAs serially
diluted into a constant amount (1 p.g) of HIV-negative human
PBMC RNA (32). For amplification of HIV-1 proviral se-
quences, I pLg of DNA in 2 pl was added to 50-pl PCR
mixtures otherwise identical to those used to amplify cDNA
specific for US HIV-1 RNA.
RESULTS
PBMCs and parts of LN were obtained from three HIV-1-
infected chimpanzees, C-487, C-435, and C-120, and used for
nucleic acid extractions (see Materials and Methods). HIV-
specific DNA and RNA were measured by PCR and RT-PCR
with two different sets of amplification primers that match
precisely the HIV-lLai sequence of the viral strains used to
infect the animals. One set of primers was located on each side
of the major splice donor site in the 5' region of the virus and
was used to amplify a 160-bp fragment specific for HIV
proviral DNA and cDNA derived from US HIV RNA. US
HIV RNA could represent genomic RNA in viral particles or
intracellular full-length HIV mRNA. Another set of primers
separated by the intron between the two coding exons of tat
and rev was used to amplify a 131-bp fragment from cDNA
representing MS HIV mRNA. MS HIV mRNA is obligately
intracellular and therefore reflects ongoing viral replication.
To control for the quantity and quality of the RNA prepara-
tions and the efficiency of subsequent cDNA synthesis, RT-
PCR specific for 1-actin mRNA was also performed.
As shown in Fig. IA, no MS HIV-1 RNA was detected in the
PBMC samples from any of the three chimpanzees (Fig. IA,
lanes P), indicating less than 50,000 molecules of MS HIV-1
mRNA per microgram of total PBMC RNA. Similarly, little or
no US HIV RNA was observed in the PBMCs. In longer
exposures of the autoradiogram, a weak signal specific for US
HIV RNA was seen in PBMCs from chimpanzee 435 (not
shown), whereas samples from the others (chimpanzees 487
and 120) were still negative. In the absence of MS HIV mRNA,
however, the low levels of US HIV mRNA signal in the PBMC
sample of chimpanzee 435 is unlikely to reflect HIV replication
and probably was caused by virus particles produced elsewhere
in the animal. The intensities of 1-actin mRNA signals from all
PBMC samples were comparable and similar to what we
typically observe when using cDNA prepared from 1 to 2 pLg of
spectrophotometrically quantitated human PBMC RNA, indi-
cating that the chimpanzee PBMC RNAs were intact and the
cDNA synthesis had been successful. Thus, no evidence of viral
replication in the PBMCs of these animals was observed.
In contrast, intense autoradiographic signals specific for US
HIV RNA were detected in LN samples from all three animals
(Fig. 1). This was even more striking considering that two of
these LN RNA preparations (435 and 120) had much less
intact RNA, as indicated by the weak 3-actin signal obtained
from these cDNAs (Fig. 1). From results for our in vitro-
transcribed HIV RNA controls and the 3-actin signals ob-
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FIG. 1. Quantitation of HIV RNA and DNA in PBMCs and LN of
HIV-1-infected chimpanzees. (A) Total RNA was extracted from
PBMCs (P) or LN (L) of chimpanzees 435, 487, and 120 and subjected
to RT-PCR specific for US HIV-1 RNA (US) or MS HIV-1 mRNA
(MS). Cellular ,B-actin mRNA in these samples was also measured.
The three PBMC RNAs and the LN RNA from chimpanzee 487 show
similar ,1-actin signals, allowing comparison of their HIV expression.
In contrast, despite similar spectrophotometrically determined RNA
concentrations, the LN RNAs from chimpanzees 435 and 120 used for
RT-PCR show only weak I-actin signals, indicating degradation of
these samples. Lane C shows an analysis of a control sample containing
0.5 x 106 copies of both US and MS HIV-1 RNA per microgram of
total cellular RNA. (B) DNA was isolated from the PBMCs (P) and
LN (L) from chimpanzee 487, and 1 pLg of each was analyzed for
HIV-1 content by PCR, using the same primers as in US RT-PCR.
Thus, the targeted PCR fragment is derived from the 5' region of the
virus just 3' of the primer binding site and can be amplified only from
more mature products of reverse transcription.
tained, we estimated that the LN RNA from animal 487
contained approximately 20 million copies of unspliced HIV
RNA per microgram of total RNA. Although HIV RNA and
cellular ,3-actin mRNA may be degraded at different rates,
such calculations suggested that the viral load in the LN
samples from animals 120 and 435 was even higher than that in
the sample from animal 487.
The quality of the LN RNA from animal 487 allowed a
reliable quantitative analysis of the different HIV RNA spe-
cies. This RNA sample showed a readily detectable MS RNA
signal under the linear and quantitative conditions of our assay
(Fig. 1A) and was estimated to contain approximately 200,000
copies of MS HIV-1 mRNA per microgram of total RNA.
Whether similar levels of MS HIV-1 mRNA were present in
the LN samples of animals 435 and 120 could not be assessed
because of the poor quality of these RNA preparations.
Nevertheless, the result clearly demonstrates that active viral
replication can occur in the lymphatic tissues of HIV-infected
chimpanzees even when it is not detectable in the peripheral
blood.
The amount of MS HIV-1 RNA in the LN of chimpanzee
487 was, however, less than 1% of that of US HIV-1 RNA.
Such a dramatic difference in the ratio of these differentially
spliced HIV RNAs is probably due to the fact that most of the
US HIV RNA signal is derived from viral particles trapped in
the LN and not from intracellular full-length HIV mRNA. This
interpretation is in agreement with published in situ hybridiza-
tion studies showing that most of the abundant HIV RNA
present in the LN of HIV-infected humans is located extracel-
lularly associated with the dendritic follicular cells (8, 28).
To examine the relative numbers of HIV-infected cells,
genomic DNA was prepared from the PBMCs of chimpanzee
[3-actin-*- _.j _0_ _ w__
FIG. 2. In vitro activation of latent HIV in PBMCs from chimpan-
zee 487. The Ficoll-purified PBMCs from 75 ml of blood from
chimpanzee 487 were diluted into culture medium and split into six
identical aliquots. One was harvested immediately (0), the rest were
first cultured for the indicated times (days [d]) in the presence of 100
nM PMA and 2 ig of PHA per ml. Two micrograms of total RNA
from each sample was analyzed by RT-PCR as in Fig. IA.
487 and from another part of the same LN of this animal that
had been analyzed for its HIV RNA content. One microgram
of each DNA was then used as the template for PCR ampli-
fication employing the primers and reaction conditions estab-
lished for the US RT-PCR assay. The number of HIV-1
proviruses per microgram of genomic DNA was found to be
approximately 10-fold higher in the lymphatic tissue than in
the PBMCs (Fig. 1B). A similar ratio was observed between
the LN and PBMCs of another chimpanzee (animal 411; data
not shown) for which no LN RNA was available for RT-PCR
analysis. Thus, the increased expression of HIV-1 RNA in the
lymph nodes of HIV-infected chimpanzees is accompanied by
a higher number of proviruses than in their peripheral blood.
Although we found no evidence of viral replication in the
peripheral blood, the intensity of HIV-specific DNA signal
suggested that 1/1,000 to 1/10,000 of the PBMCs of chimpan-
zee 487 carried a provirus. To test whether viral replication
could be induced in these cells by cellular activation, we
collected a larger blood sample from this animal and analyzed
HIV-1 mRNA expression in these PBMCs before and after
stimulation in vitro with 100 nM PMA and 2 ,ug of PHA per
ml. This second blood sample, collected more than 6 months
after the first, confirmed the lack of HIV mRNA expression in
the unstimulated PBMCs and indicated that this phenotype is
stable over time. However, after only 12 h of stimulation in
vitro, HIV gene expression was evident, and both MS and US
HIV-1 mRNAs were readily detected by RT-PCR (Fig. 2).
Since this time is too short to allow spread of virus in the
culture, the induced HIV expression could not have derived
from newly infected cells and must have been due to virus
production by latently infected cells present in the original
sample. This induction occurred rapidly and was already
maximal at the 12-h time point. The expression of HIV mRNA
relative to the total PBMC RNA thereafter decreased up to 3
days. However, in the sample collected after 1 week in culture,
increased expression, even higher than that in the 12-h sample,
was observed. This delayed increase in HIV expression was
presumably due to spreading of the infection in the culture,
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indicating that activation of latent HIV in these cells also
resulted in production of infectious virus.
DISCUSSION
In this study, we have shown that high levels of HIV are
associated with LN but not PBMCs of HIV-infected chimpan-
zees and that viral replication could be demonstrated in LN but
not in PBMCs of these animals. This situation is strikingly
similar to that seen in certain asymptomatic HIV-infected
humans. Recent studies have revealed that active infection
takes place in the lymphatic tissues throughout the clinically
latent period of HIV infection when very little or no HIV
mRNA can be detected in the peripheral blood (28).
Thus, these results provide substantial new support for the
notion that HIV-infected chimpanzees may be a relevant
model with which to study the cellular and molecular mecha-
nisms regulating the clinical latency of HIV disease in humans.
Specifically, these animals could be valuable in understanding
the role of the lymphatic tissue in the establishment of a
persistent HIV infection. Also, after the acute viremic phase of
infection is over, HIV-infected chimpanzees probably repre-
sent a rather homogeneous population in regard to the repli-
cative state of their virus, and this virus-host interaction could
share significant pathobiological features with the subpopula-
tion of human long-term survivors of HIV infection.
The sensitivity of our RT-PCR assay allowed us to deter-
mine the cellular basis of the lack of HIV expression in the
peripheral blood of these chimpanzees. By directly monitoring
HIV mRNA expression in the rare subpopulation of PBMCs
carrying a provirus, we demonstrated rapid and efficient acti-
vation of HIV production in these cells upon mitogenic
stimulation in vitro. Therefore, we conclude that cellular
latency of HIV does indeed exist in vivo. HIV-1 DNA-positive
cells which express no detectable HIV mRNA are also present
in the peripheral blood (30) and lymphatic tissues (8) of
HIV-infected humans. Given the present results, it is possible
that the proviruses in many, if not most, of these cells can be
activated to produce infectious virus. Interestingly, our prelim-
inary studies to address this issue have shown that HIV mRNA
expression can be similarly activated by PMA-PHA treatment
of human PBMCs (33).
The PMA-PHA-induced activation of latent HIV in chim-
panzee PBMCs was similar to the proviral activation observed
in certain cell line models of HIV latency (10, 11). These
latently infected cell lines have been derived from single cells
which have survived the lytic effects of HIV after infection of
human T-cell and monocytic leukemia cell cultures. Such cell
lines support only very low levels of viral replication when
cultured in an unstimulated state but can be induced to
produce high amounts of virus when exposed to agents such as
PMA and PHA or cytokines such as tumor necrosis factor
alpha. The increased virus production after such stimulation of
these cells is accompanied by a highly induced expression of
HIV mRNA (31). Much of this induction is believed to be
mediated by interaction of the transcription factor NF-KB with
its two tandemly arranged cognate sites in the proviral long
terminal repeat element (6, 24). Thus, it is likely that the
increased activity of NF-KB, or a closely related factor, is
involved in the activation of latent HIV in the in vitro-
stimulated chimpanzee PBMCs. Transcriptional quiescence of
integrated proviruses, however, may not be the only molecular
mechanism of HIV cellular latency. It has been shown that
unintegrated HIV can persist for extended times in infected
cells and continue the viral life cycle once the host cell is
activated (36, 38). Our findings do not exclude a role for such
a preintegration form of HIV latency. Nevertheless, the
present results directly demonstrate the existence of cellular
latency of HIV in vivo and provide a useful model with which
to further dissect the molecular mechanism involved.
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